The latest price target for IGM Biosciences (NASDAQ:IGMS) was reported by HC Wainwright & Co. on September 5, 2024. The analyst firm set a price target for $11.00 expecting IGMS to fall to within 12 months (a possible -40.48% downside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for IGM Biosciences (NASDAQ:IGMS) was provided by HC Wainwright & Co., and IGM Biosciences maintained their neutral rating.

The last upgrade for IGM Biosciences Inc happened on February 9, 2024 when RBC Capital raised their price target to $21. RBC Capital previously had a sector perform for IGM Biosciences Inc.

The last downgrade for IGM Biosciences Inc happened on December 15, 2023 when B of A Securities changed their price target from N/A to $8 for IGM Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IGM Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IGM Biosciences was filed on September 5, 2024 so you should expect the next rating to be made available sometime around September 5, 2025.

While ratings are subjective and will change, the latest IGM Biosciences (IGMS) rating was a maintained with a price target of $12.00 to $11.00. The current price IGM Biosciences (IGMS) is trading at is $18.48, which is out of the analyst’s predicted range.